1. LINC01133 promotes pancreatic ductal adenocarcinoma epithelial-mesenchymal transition mediated by SPP1 through binding to Arp3.
- Author
-
Yang Y, Gong Y, Ding Y, Sun S, Bai R, Zhuo S, and Zhang Z
- Subjects
- Animals, Female, Humans, Male, Mice, Apoptosis, Cell Line, Tumor, Cell Movement, Gene Expression Regulation, Neoplastic, Mice, Inbred BALB C, Mice, Nude, Prognosis, Actin-Related Protein 3 metabolism, Actin-Related Protein 3 genetics, Carcinoma, Pancreatic Ductal pathology, Carcinoma, Pancreatic Ductal metabolism, Carcinoma, Pancreatic Ductal genetics, Cell Proliferation, Epithelial-Mesenchymal Transition genetics, Osteopontin metabolism, Osteopontin genetics, Pancreatic Neoplasms pathology, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms genetics, RNA, Long Noncoding genetics, RNA, Long Noncoding metabolism
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited treatment methods. Long non-coding RNAs (lncRNAs) have been found involved in tumorigenic and progression. The present study revealed that LINC01133, a fewly reported lncRNA, was one of 16 hub genes that could predict PDAC patients' prognosis. LINC01133 was over-expressed in PDAC tumors compared to adjacent pancreas and could promote PDAC proliferation and metastasis in vitro and in vivo, as well as inhibit PDAC apoptosis. LINC01133 expression positively correlated to secreted phosphoprotein 1 (SPP1) expression, leading to an enhanced epithelial-mesenchymal transition (EMT) process. LINC01133 bound with actin-related protein 3 (Arp3), the complex reduced SPP1 mRNA degradation which increased SPP1 mRNA level, ultimately leading to PDAC proliferation. This research revealed a novel mechanism of PDAC development and provided a potential prognosis indicator that may benefit PDAC patients., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF